131 related articles for article (PubMed ID: 17003679)
1. Antiretroviral therapy and HIV prevention in India: modeling costs and consequences of policy options.
Over M; Marseille E; Sudhakar K; Gold J; Gupta I; Indrayan A; Hira S; Nagelkerke N; Rao AS; Heywood P
Sex Transm Dis; 2006 Oct; 33(10 Suppl):S145-52. PubMed ID: 17003679
[TBL] [Abstract][Full Text] [Related]
2. The economics of effective AIDS treatment in Thailand.
Over M; Revenga A; Masaki E; Peerapatanapokin W; Gold J; Tangcharoensathien V; Thanprasertsuk S
AIDS; 2007 Jul; 21 Suppl 4():S105-16. PubMed ID: 17620745
[TBL] [Abstract][Full Text] [Related]
3. Assessing efficiency and costs of scaling up HIV treatment.
Cleary SM; McIntyre D; Boulle AM
AIDS; 2008 Jul; 22 Suppl 1():S35-42. PubMed ID: 18664951
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia.
Long EF; Brandeau ML; Galvin CM; Vinichenko T; Tole SP; Schwartz A; Sanders GD; Owens DK
AIDS; 2006 Nov; 20(17):2207-15. PubMed ID: 17086061
[TBL] [Abstract][Full Text] [Related]
5. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness.
Desai K; Sansom SL; Ackers ML; Stewart SR; Hall HI; Hu DJ; Sanders R; Scotton CR; Soorapanth S; Boily MC; Garnett GP; McElroy PD
AIDS; 2008 Sep; 22(14):1829-39. PubMed ID: 18753932
[TBL] [Abstract][Full Text] [Related]
6. Recurrent costs of HIV/AIDS-related health services in Rwanda: implications for financing.
Quentin W; König HH; Schmidt JO; Kalk A
Trop Med Int Health; 2008 Oct; 13(10):1245-56. PubMed ID: 18721185
[TBL] [Abstract][Full Text] [Related]
7. Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006.
Krentz HB; Gill MJ
HIV Med; 2008 Oct; 9(9):721-30. PubMed ID: 18643856
[TBL] [Abstract][Full Text] [Related]
8. Costs, consequences and feasibility of strategies for achieving the goals of the National HIV/AIDS strategy in the United States: a closing window for success?
Holtgrave DR; Hall HI; Wehrmeyer L; Maulsby C
AIDS Behav; 2012 Aug; 16(6):1365-72. PubMed ID: 22610372
[TBL] [Abstract][Full Text] [Related]
9. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings.
Bishai D; Colchero A; Durack DT
AIDS; 2007 Jun; 21(10):1333-40. PubMed ID: 17545710
[TBL] [Abstract][Full Text] [Related]
10. Costs and benefits of HAART for patients with HIV in a public hospital in Mexico.
Aracena-Genao B; Navarro JO; Lamadrid-Figueroa H; Forsythe S; Trejo-Valdivia B
AIDS; 2008 Jul; 22 Suppl 1():S141-8. PubMed ID: 18664946
[TBL] [Abstract][Full Text] [Related]
11. The Chinese free antiretroviral treatment program: challenges and responses.
Zhang F; Haberer JE; Wang Y; Zhao Y; Ma Y; Zhao D; Yu L; Goosby EP
AIDS; 2007 Dec; 21 Suppl 8():S143-8. PubMed ID: 18172383
[TBL] [Abstract][Full Text] [Related]
12. Predictors of failure of first-line antiretroviral therapy in HIV-infected adults: Indian experience.
Rajasekaran S; Jeyaseelan L; Vijila S; Gomathi C; Raja K
AIDS; 2007 Jul; 21 Suppl 4():S47-53. PubMed ID: 17620752
[TBL] [Abstract][Full Text] [Related]
13. Country-wide distribution of the nitrile female condom (FC2) in Brazil and South Africa: a cost-effectiveness analysis.
Dowdy DW; Sweat MD; Holtgrave DR
AIDS; 2006 Oct; 20(16):2091-8. PubMed ID: 17053355
[TBL] [Abstract][Full Text] [Related]
14. Examining catastrophic costs and benefit incidence of subsidized antiretroviral treatment (ART) programme in south-east Nigeria.
Onwujekwe O; Dike N; Chukwuka C; Uzochukwu B; Onyedum C; Onoka C; Ichoku H
Health Policy; 2009 May; 90(2-3):223-9. PubMed ID: 19036466
[TBL] [Abstract][Full Text] [Related]
15. Economic impact of HIV.
Veenstra N; Whiteside A
Best Pract Res Clin Obstet Gynaecol; 2005 Apr; 19(2):197-210. PubMed ID: 15778110
[TBL] [Abstract][Full Text] [Related]
16. The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa.
Rosen S; Long L; Sanne I
Trop Med Int Health; 2008 Aug; 13(8):1005-15. PubMed ID: 18631314
[TBL] [Abstract][Full Text] [Related]
17. The private sector and HIV/AIDS in Africa: taking stock of 6 years of applied research.
Rosen S; Feeley F; Connelly P; Simon J
AIDS; 2007 Jul; 21 Suppl 3():S41-51. PubMed ID: 17666961
[TBL] [Abstract][Full Text] [Related]
18. Sexuality, reproduction, and HIV in women: the impact of antiretroviral therapy in elective pregnancies in Cuba.
Castro A; Khawja Y; González-Núñez I
AIDS; 2007 Oct; 21 Suppl 5():S49-54. PubMed ID: 18090268
[TBL] [Abstract][Full Text] [Related]
19. Combining prevention, treatment and care: lessons from South Africa.
Achmat Z; Simcock J
AIDS; 2007 Jul; 21 Suppl 4():S11-20. PubMed ID: 17620746
[TBL] [Abstract][Full Text] [Related]
20. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
Pinheiro Edos S; Antunes OA; Fortunak JM
Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
